April 12, 2021
25 min listen
Save
Alimera Sciences & Iluvien: A New Day
In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology.
- Intro :13
- In this episode :18
- About Rick Eiswirth :23
- What’s your background? How did you get into the ophthalmology industry? 0:51
- What are the benefits of Iluvien (fluocinolone acetonide, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36
- How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26
- Can you tell us more about the New Day trial? 8:10
- Which trial outcome would be considered a success for Iluvien? 11:58
- Do you anticipate a cost savings? 13:58
- What’s the status of the New Day trial? 15:15
- How has COVID changed the industry landscape in ophthalmology? 16:20
- Are there any new products in the pipeline? 18:38
- Iluvien is approved in other countries for uveitis 20:36
- What have you seen from retina specialists; are there longer efficacy rates? 22:10
- What do you think is the most important challenge the ophthalmic community will face in the future? 23:17
- Thanks for listening 24:36
Rick Eiswirth is president and CEO of Alimera Sciences.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
Read more about
